Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants?

PURPOSE: This study aims to determine a velocity threshold in the main renal vein (MRV) of renal transplants and evaluate the cause and clinical significance of elevated velocity. METHODS: Maximum MRV velocity from 331 consecutive renal transplant Doppler ultrasounds in 170 patients was recorded. A priori, twice the median MRV velocity was selected as the threshold for elevation. Ultrasounds were divided into "early" and "late" periods based on time after transplantation. Charts were reviewed for outcomes associated with elevated MRV velocity. Endpoints included graft failure or death. Serum creatinine (Cr) levels among groups were compared, and temporal changes in MRV velocity were plotted. RESULTS: A ≥70 cm/s was chosen as the threshold for elevated MRV velocity. Graft failure and complication/intervention rates were higher only in the "late" group with elevated MRV velocity. There was no association between elevated MRV velocity and death, no predilection for a particular biopsy result, and no difference in Cr levels among groups. The majority of elevated velocities occurred during the immediate postoperative period and resolved without intervention. CONCLUSIONS: Elevated MRV velocity in the early postoperative period is a transient phenomenon not correlating with outcome or requiring intervention. In the late period, elevated MRV velocity is associated with entities including hydronephrosis, perinephric collections, and arteriovenous fistulae.

Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.

Although mantle cell lymphoma (MCL) frequently harbors inactivated ataxia telangiectasia mutated (ATM) and p53 alleles, little is known about the molecular phenotypes caused by these genetic changes. We identified point mutations and genomic deletions in these genes in a series of cyclin D1-positive MCL cases and correlated genotype with gene expression profiles and overall survival. Mutated and/or deleted ATM and p53 alleles were found in 56% (40/72) and 26% (21/82) of the cases examined, respectively. Although MCL patients with inactive p53 alleles showed a significant reduction in median overall survival, aberrant ATM status did not predict for survival. Nevertheless, specific gene expression signatures indicative of the mutation and genomic deletion status of each gene were identified that were different from wild-type cases. These signatures were comprised of a select group of genes related to apoptosis, stress responses, and cell cycle regulation that are relevant to ATM or p53 function. Importantly, we found the molecular signatures are different between cases with mutations and deletions, because the latter are characterized by loss of genes colocalized in the same chromosome region of ATM or p53. This information on molecular phenotypes may provide new areas of investigation for ATM function or may be exploited by designing specific therapies for MCL cases with p53 aberrations.